# DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

> **NCT06075953** · PHASE2 · RECRUITING · sponsor: **QuantumLeap Healthcare Collaborative** · enrollment: 400 (estimated)

## Conditions studied

- Ductal Carcinoma in Situ

## Interventions

- **DRUG:** Tamoxifen
- **DRUG:** Exemestane
- **DRUG:** Letrozole
- **DRUG:** Anastrazole
- **DRUG:** Testosterone + Anastrazole
- **DRUG:** Elacestrant
- **DRUG:** Z-endoxifen

## Key facts

- **NCT ID:** NCT06075953
- **Lead sponsor:** QuantumLeap Healthcare Collaborative
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-17
- **Primary completion:** 2028-11
- **Final completion:** 2033-11
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06075953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06075953, "DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT06075953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*